Publications

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.

Dupont T, Yang SNing, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.  2016.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.. Oncotarget. 7(3):3520-32.

Marullo R, Rutherford SC, Leonard JP, Cerchietti L.  2016.  Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.. Cell Cycle. 15(17):2241-7.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Goldstein RL, Yang SNing, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G et al..  2015.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.. J Clin Invest. 125(12):4559-71.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA.  2015.  The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.. Oncogene. 34(9):1073-82.

Zahreddine HAhmad, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E et al..  2014.  The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.. Nature. 511(7507):90-3.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Ruan J, Luo M, Wang C, Fan L, Yang SNing, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L et al..  2013.  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.. Blood. 121(26):5192-202.

Ruan J, Luo M, Wang C, Fan L, Yang SNing, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L et al..  2013.  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.. Blood. 121(26):5192-202.

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

Cerchietti L, Leonard JP.  2013.  Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.. Hematology Am Soc Hematol Educ Program. 2013:591-5.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.